Business
    Next Score View the next score

    Mass. Movers

    Celldex studying kidney disease therapy

    Celldex has started a pilot study on a new treatment.
    istockphoto.com
    Celldex has started a pilot study on a new treatment.

    Shares of Celldex Therapeutics continued to rise on Friday, four days after the company said it has begun a pilot study of a treatment for a rare kidney disease called dense deposit disease. Celldex said the first patient was dosed in the study of the disease, which ultimately results in kidney failure for most patients. Celldex has its operations office in Needham and also operates a manufacturing plant in Fall River, among other facilities in the Northeast.